Literature DB >> 20177358

CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART.

Marta Massanella1, Eugenia Negredo, Nuria Pérez-Alvarez, Jordi Puig, Raul Ruiz-Hernández, Margarita Bofill, Bonaventura Clotet, Julià Blanco.   

Abstract

BACKGROUND: The failure to increase CD4 T-cell counts in some HAART-treated HIV-infected patients with satisfactory virological responses has been related to low CD4 T-cell production, high turnover and death. However, the relative contribution of these factors is still unclear, strongly limiting the definition of appropriate therapeutic strategies for these patients.
METHODS: A cross-sectional study was designed to evaluate the contribution of thymic activity, microbial translocation, cellular activation and death to CD4 T-cell recovery. We included 230 HIV-infected individuals on suppressive HAART (>2 years); 95 of them were considered 'discordant' (CD4 T-cell count <350 cells/mul) and 135 were considered 'concordant'. Comparative and logistic regression analyses were performed.
RESULTS: Discordant patients showed higher levels of activated [human leukocyte antigen (HLA)-DRCD95 and CD38CD45RA] cells in both the CD8 and CD4 T-cell compartments. Notably, the most significant differences were observed in CD4 T cells. Discordant patients showed lower naive CD4 T-cell production (CD45RACD31 cells), higher spontaneous ex-vivo CD4 T-cell death and higher plasma levels of soluble CD14. Multivariate analysis showed that activation and death of CD4 T cells, along with nadir CD4 T-cell counts, were the only predictive factors for poor immune recovery. Moreover, the low correlations found between CD4 T-cell activation or death with thymic output and bacterial translocation suggest that additional factors modulate cellular activation and death and, in turn, CD4 T-cell recovery.
CONCLUSION: CD4 T-cell repopulation during HAART is determined by CD4 T-cell activation and death. Therefore, strategies aimed to reduce these parameters should be envisaged to treat discordant patients.

Entities:  

Mesh:

Year:  2010        PMID: 20177358     DOI: 10.1097/QAD.0b013e328337b957

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  60 in total

Review 1.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

2.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Authors:  Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 4.  Mucosal immunity in human and simian immunodeficiency lentivirus infections.

Authors:  J M Brenchley
Journal:  Mucosal Immunol       Date:  2013-04-03       Impact factor: 7.313

5.  Virome analysis of antiretroviral-treated HIV patients shows no correlation between T-cell activation and anelloviruses levels.

Authors:  Linlin Li; Xutao Deng; Antonio Charlys Da Costa; Roberta Bruhn; Steven G Deeks; Eric Delwart
Journal:  J Clin Virol       Date:  2015-10-08       Impact factor: 3.168

6.  A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

Authors:  Timothy J Wilkin; Christina M Lalama; John McKinnon; Rajesh T Gandhi; Nina Lin; Alan Landay; Heather Ribaudo; Lawrence Fox; Judith S Currier; John W Mellors; Roy Gulick; Allan R Tenorio
Journal:  J Infect Dis       Date:  2012-06-27       Impact factor: 5.226

Review 7.  Microbial translocation, immune activation, and HIV disease.

Authors:  Nichole R Klatt; Nicholas T Funderburg; Jason M Brenchley
Journal:  Trends Microbiol       Date:  2012-10-11       Impact factor: 17.079

8.  Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Authors:  Xinyan Zhang; Peter W Hunt; Scott M Hammer; Michelle S Cespedes; Kristine B Patterson; Ronald J Bosch
Journal:  HIV Clin Trials       Date:  2013 Mar-Apr

Review 9.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

10.  Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Authors:  Eugènia Negredo; Marta Massanella; Maria C Puertas; Maria J Buzón; Jordi Puig; Núria Pérez-Alvárez; Josué Pérez-Santiago; Anna Bonjoch; José Moltó; Antoni Jou; Patricia Echeverría; Josep M Llibre; Javier Martínez-Picado; Bonaventura Clotet; Julià Blanco
Journal:  J Antimicrob Chemother       Date:  2013-05-14       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.